Beodeul Kang

2.4k total citations
99 papers, 1.4k citations indexed

About

Beodeul Kang is a scholar working on Oncology, Hepatology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Beodeul Kang has authored 99 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Oncology, 26 papers in Hepatology and 25 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Beodeul Kang's work include Hepatocellular Carcinoma Treatment and Prognosis (26 papers), Cancer Immunotherapy and Biomarkers (18 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (16 papers). Beodeul Kang is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (26 papers), Cancer Immunotherapy and Biomarkers (18 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (16 papers). Beodeul Kang collaborates with scholars based in South Korea, United States and Japan. Beodeul Kang's co-authors include Hong Jae Chon, Chan Kim, Jaekyung Cheon, Hye Jin Choi, Hyun Cheol Chung, Sun Young Rha, Hannah Yang, Won Suk Lee, Choong‐kun Lee and Ho Yeong Lim and has published in prestigious journals such as Nature Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Beodeul Kang

90 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Beodeul Kang South Korea 21 756 373 344 322 199 99 1.4k
Jaekyung Cheon South Korea 22 720 1.0× 365 1.0× 477 1.4× 487 1.5× 198 1.0× 92 1.4k
Sulaiman Nanji Canada 24 735 1.0× 294 0.8× 319 0.9× 742 2.3× 183 0.9× 80 1.6k
Timothy E. Newhook United States 21 676 0.9× 404 1.1× 224 0.7× 678 2.1× 132 0.7× 132 1.5k
David A. Smith United Kingdom 19 420 0.6× 506 1.4× 170 0.5× 560 1.7× 103 0.5× 53 1.5k
Ludger Staib Germany 24 1.2k 1.6× 430 1.2× 129 0.4× 581 1.8× 177 0.9× 73 1.8k
Todd D. Francone United States 18 808 1.1× 261 0.7× 150 0.4× 826 2.6× 91 0.5× 63 1.5k
Felix Krenzien Germany 21 518 0.7× 418 1.1× 447 1.3× 763 2.4× 144 0.7× 137 1.5k
Jean‐Christophe Weber France 22 901 1.2× 326 0.9× 815 2.4× 781 2.4× 163 0.8× 60 1.7k
Stefania Salvagni Italy 21 1.2k 1.6× 527 1.4× 166 0.5× 172 0.5× 67 0.3× 46 1.7k
Lawrence Schwartz United States 18 446 0.6× 512 1.4× 232 0.7× 267 0.8× 153 0.8× 39 1.6k

Countries citing papers authored by Beodeul Kang

Since Specialization
Citations

This map shows the geographic impact of Beodeul Kang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beodeul Kang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beodeul Kang more than expected).

Fields of papers citing papers by Beodeul Kang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Beodeul Kang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beodeul Kang. The network helps show where Beodeul Kang may publish in the future.

Co-authorship network of co-authors of Beodeul Kang

This figure shows the co-authorship network connecting the top 25 collaborators of Beodeul Kang. A scholar is included among the top collaborators of Beodeul Kang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Beodeul Kang. Beodeul Kang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ryoo, Baek‐Yeol, Hong Jae Chon, Hyung‐Don Kim, et al.. (2025). Multicenter Phase 2 Trial of Second-Line Regorafenib in Patients with Unresectable Hepatocellular Carcinoma after Progression on Atezolizumab plus Bevacizumab. Liver Cancer. 14(4). 446–455. 2 indexed citations
2.
3.
Jung, Eun Hee, Yusuke Hiratsuka, Sang‐Yeon Suh, et al.. (2024). Clinicians’ Prediction of Survival Is Most Useful for Palliative Care Referral. SHILAP Revista de lepidopterología. 5(1). 365–372.
4.
Kim, Seul‐Gi, et al.. (2024). Impact of Coronavirus Disease 2019 on Unresectable Hepatocellular Carcinoma Treated with Atezolizumab/Bevacizumab. Journal of Clinical Medicine. 13(5). 1335–1335. 1 indexed citations
5.
Kim, Hyung‐Don, Ho Yeong Lim, Baek‐Yeol Ryoo, et al.. (2024). Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial. Nature Medicine. 30(3). 699–707. 29 indexed citations
6.
Kwon, Jung Hye, Seung‐Hoon Beom, Sang Joon Shin, et al.. (2023). Outcomes of an Acute Palliative Care Unit at a Comprehensive Cancer Center in Korea. SHILAP Revista de lepidopterología. 4(1). 9–16. 1 indexed citations
7.
8.
Jung, Eun Hee, Yu Jung Kim, Beodeul Kang, et al.. (2022). Clinical Outcomes of Operating an Acute Palliative Care Unit at a Comprehensive Cancer Center. JCO Oncology Practice. 18(10). e1661–e1671. 8 indexed citations
9.
Kim, Yu Jung, Sang‐Yeon Suh, Yusuke Hiratsuka, et al.. (2022). Performance of clinician prediction of survival in oncology outpatients with advanced cancer. PLoS ONE. 17(4). e0267467–e0267467. 7 indexed citations
10.
Hiratsuka, Yusuke, Yu Jung Kim, Sang‐Yeon Suh, et al.. (2022). The association between changes in symptoms or quality of life and overall survival in outpatients with advanced cancer. Annals of Palliative Medicine. 11(7). 2338–2348. 4 indexed citations
11.
Cheon, Jaekyung, et al.. (2022). Organ-specific responses to atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma.. Journal of Clinical Oncology. 40(16_suppl). 4076–4076. 3 indexed citations
12.
13.
Yoo, Changhoon, Seonggyu Byeon, Jaekyung Cheon, et al.. (2020). Regorafenib in previously treated advanced hepatocellular carcinoma: Impact of prior immunotherapy and adverse events. Liver International. 40(9). 2263–2271. 31 indexed citations
14.
Kim, Hyung‐Don, Myung Ah Lee, Jin Won Kim, et al.. (2020). Regorafenib in patients with advanced Child‐Pugh B hepatocellular carcinoma: A multicentre retrospective study. Liver International. 40(10). 2544–2552. 34 indexed citations
15.
Lee, Won Suk, Chang Woo Kim, Seung Joon Lee, et al.. (2020). Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer. Journal for ImmunoTherapy of Cancer. 8(2). e000857–e000857. 47 indexed citations
16.
Kang, Beodeul, Ji‐Won Kim, Se Hyun Kim, et al.. (2020). Symptom burden and characteristics of patients who die in the acute palliative care unit of a tertiary cancer center. Annals of Palliative Medicine. 9(2). 216–223. 6 indexed citations
17.
Park, Ji Soo, Beodeul Kang, Yehyun Park, et al.. (2019). Screening for Lung Cancer Using Low-dose Chest Computed Tomography in Korean Long-term Colorectal Cancer Survivors. Journal of Cancer Prevention. 24(1). 48–53. 2 indexed citations
18.
19.
Choi, In Sil, Ju Hyun Lee, Jee Hyun Kim, et al.. (2018). Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study. PLoS ONE. 13(6). e0198544–e0198544. 18 indexed citations
20.
Lim, Sun Min, Youn Nam Kim, Ki Hyun Park, et al.. (2016). Bone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patients. BMC Cancer. 16(1). 385–385. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jaekyung Cheon Breakdown of academic impact, for papers by Sulaiman Nanji Breakdown of academic impact, for papers by Timothy E. Newhook Breakdown of academic impact, for papers by David A. Smith Breakdown of academic impact, for papers by Ludger Staib Breakdown of academic impact, for papers by Todd D. Francone Breakdown of academic impact, for papers by Felix Krenzien Breakdown of academic impact, for papers by Jean‐Christophe Weber Breakdown of academic impact, for papers by Stefania Salvagni Breakdown of academic impact, for papers by Lawrence Schwartz
Rankless by CCL
2026